What Is GLP-3? Mechanism, Uses, and How It Relates to Weight

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides and GLP-1 education

"what is glp 3" covers a common search-term misunderstanding. GLP-1 is a real hormone pathway and medication category. GLP-2 is also a real gut peptide pathway. "GLP-3," however, is not a standard FDA-approved medication class, a recognized clinical prescribing term, or the correct name for next-generation weight-management drugs. This article explains what people usually mean when they search for GLP-3, how GLP-1 and incretin-based medications work, and how upstream genetics can help frame a more informed provider conversation.

What GLP-3 is

"GLP-3" is not a recognized peptide hormone or FDA-approved drug class in the way GLP-1 and GLP-2 are recognized biological pathways. In practice, searches for "what is GLP-3" usually reflect confusion around one of several real topics: GLP-1 receptor agonists, dual GIP/GLP-1 agonists such as tirzepatide, investigational triple agonists such as retatrutide, or GLP-2 therapies used in separate clinical contexts. Retatrutide, for example, is not "GLP-3." It is an investigational triple hormone receptor agonist designed to activate GIP, GLP-1, and glucagon receptors. See the PlexusDx primer What is GLP-1? for the pathway-level background.

How it works

Because GLP-3 is not a defined clinical drug class, the more accurate question is how GLP-1 and incretin-based medications work. GLP-1 receptor agonists engage the GLP-1 receptor, a pathway involved in appetite regulation, satiety, gastric emptying, glucose-dependent insulin secretion, and post-meal glucose control. Dual GIP/GLP-1 agonists such as tirzepatide also engage the GIP receptor, adding another incretin pathway. Investigational triple agonists such as retatrutide are designed to engage GIP, GLP-1, and glucagon receptors, but retatrutide is not FDA-approved and should not be purchased or used outside legitimate clinical-trial oversight.

What it is used for

There is no FDA-approved medication indication for "GLP-3" because GLP-3 is not a standard approved medication class. FDA-approved GLP-1 and incretin-pathway medications are used under specific brand labels and indications, which may include type 2 diabetes, chronic weight management, cardiovascular risk reduction in certain populations, and moderate-to-severe obstructive sleep apnea in adults with obesity for Zepbound. Prescribing depends on the specific medication, brand, indication, contraindications, and clinical judgment. Investigational triple agonists such as retatrutide are being studied in clinical trials and are not available through ordinary prescribing, retail pharmacy, compounding pharmacy, or direct-to-consumer purchase.

Common side effects

Because GLP-3 is not a defined medication category, it does not have its own established side-effect profile or FDA-approved label. For GLP-1 and incretin-based medications, gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite are commonly discussed, especially during dose escalation. Medication-specific risks vary by product and should be reviewed using the approved label and a qualified healthcare provider’s guidance. Products marketed online as "GLP-3," "research" retatrutide, or unapproved GLP-1 peptides may have unknown quality, potency, sterility, dosing accuracy, and safety risks.

Cost and access

There is no legitimate retail price, insurance price, savings-card pathway, or pharmacy price for "GLP-3" because GLP-3 is not an FDA-approved medication class. Costs for FDA-approved GLP-1 and incretin-pathway medications vary by brand, dose, pharmacy, insurance coverage, prior-authorization rules, approved indication, and manufacturer savings-card eligibility. Investigational products such as retatrutide do not have legitimate direct-to-consumer pricing and should not be purchased online. Any website advertising "GLP-3" injections, "research" retatrutide, or compounded retatrutide for human use should be treated as a serious safety and legitimacy concern.

PlexusDx offers semaglutide and tirzepatide pathways through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R that may shape baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into a more informed conversation with your healthcare provider.

Related reading on PlexusDx: GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1? (overview).

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs conversations about GLP-1 and incretin-pathway protocols. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide pathways, including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds. Retatrutide is investigational and is not currently FDA-approved. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not diagnose disease, determine medication eligibility, or predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology underneath every decision. Take the Precision Peptide Genetic Test, or explore the protocol directly.

Frequently Asked Questions

What is GLP-3?

GLP-3 is not a standard FDA-approved medication class or recognized clinical prescribing term. People searching for GLP-3 usually mean GLP-1 receptor agonists, dual GIP/GLP-1 medications such as tirzepatide, the separate GLP-2 pathway, or investigational triple agonists such as retatrutide. Retatrutide is not "GLP-3"; it is an investigational GIP, GLP-1, and glucagon triple hormone receptor agonist.

How do GLP-1 receptor agonists work?

GLP-1 receptor agonists engage the GLP-1 receptor, which is involved in appetite regulation, satiety, gastric emptying, glucose-dependent insulin secretion, and post-meal glucose control. Dual GIP/GLP-1 agonists such as tirzepatide also engage the GIP receptor. Effects on weight, appetite, and glucose markers vary by medication, dose, indication, and individual clinical context.

What are GLP-1 receptor agonists used for?

GLP-1 receptor agonists and related incretin-based medications are FDA-approved for specific indications based on each product’s label. Depending on the medication and brand, those indications may include type 2 diabetes, chronic weight management, cardiovascular risk reduction in certain populations, and moderate-to-severe obstructive sleep apnea in adults with obesity for Zepbound. A qualified healthcare provider matches the medication to the indication and patient history.

Does genetic testing predict GLP-1 receptor agonist response?

No. The Precision Peptide Genetic Test does not predict response to any specific GLP-1 receptor agonist, incretin-based medication, or peptide protocol. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that may shape baseline GLP-1 and energy-balance biology — upstream context that can support a more informed conversation with a qualified healthcare provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides and GLP-1 education